Physician profile
Armando Russo
NPI 1720008386
$645.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $188 · 2021: $173.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198.19 | 2019-2021 | |
| Hologic Sales and Service, LLC | $101.72 | 2019-2021 | |
| Evofem Biosciences, INC. | $82.50 | 2020-2021 | |
| Lupin INC. | $44.23 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.77 | 2019 | |
| Covidien LP | $31.23 | 2019 | |
| Therapeuticsmd, INC. | $29.21 | 2019-2021 | |
| Astellas Pharma US INC | $27.08 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.80 | 2021 | |
| Davol INC. | $19.44 | 2021 | |
| Daiichi Sankyo INC. | $13.85 | 2020 | |
| Pfizer INC. | $13.53 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.48 | 2019 | |
| Avion Pharmaceuticals | $11.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.